Trial
NCT04064827
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AbbVie
Collaborators
—
Condition
Chronic Kidney Disease (CKD)
Intervention
Paricalcitol
Why stopped
Company Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-15